ECE2023 Poster Presentations Endocrine-related Cancer (62 abstracts)
Hand-foot syndrome: a frequent but rarely severe adverse event in patients with thyroid cancer treated with lenvatinib
Elisa Minaldi , Virginia Cappagli , Carlotta Giani , Laura Valerio , Loredana Lorusso , Antonio Matrone , Carla Gambale , Alessandro Prete , Luciana Puleo , Valeria Bottici , Eleonora Molinaro , Laura Agate & Rossella Elisei
University Hospital of Pisa, Department of Clinical and Experimental Medicine, Endocrine Unit, Pisa, Italy
Introduction: Hand-foot syndrome (HFS), or palmo-plantar erythrodysplasia, is an adverse event related to lenvatinib therapy. In the clinical trial (SELECT study) HFS was reported in 32% of patients, but only 3% was grade ≥3. In real-life studies the frequency was variable: between 8 and 55%.
Patients: We collected clinical and pathological data about 165 patients with thyroid cancer treated with lenvatinib, followed up between 2012 and 2022 at the Endocrinology Unit of the University Hospital of Pisa.
Results: Fortythree out of 165 (26.7%) developed HFS during lenvatinib treatment after a median time of 2.9 months (IQR 1.14-6.79) from the beginning of the treatment. Among these 43 cases of HFS, 24 (55.8%) were classified as grade 1, 16 (37.2%) as grade 2, 3 (7%) as grade 3/4. Because of the HFS, in 2 patients drug dose reduction was required, while in one patient a transient discontinuation of lenvatinib was necessary. All patients were treated with topical therapy. Grade ≥3 cases required podiatrist intervention and specific footwear. The comparison between those patients who developed HFS and those who did not developed HFS showed a significant association with age (mean 63±8.97 years vs 66.61±10.14; P=0.032) and duration of lenvatinib therapy [median 15.96 months (IQR 8.47-46.72) vs median 12.68 months (IQR 4.48-27.23); P=0.039]. No significant association was found concerning sex (females 29.62% vs females 23.75%), presence of distant metastasis (M1), thyroid carcinoma histotype, the starting dose of lenvatinib (mean 21.12± 4.79 mg/die vs mean 19.46± 6.04 mg/die), and prior treatments (131-I, chemotherapy, external radiotherapy, other multikinase inhibitors).
Conclusions: HFS is a frequent adverse event related to lenvatinib but rarely of grade ≥3, such as to require reduction or discontinuation of the drug. In our series, HFS was more frequent in younger patients and those who was using Lenvatinib since more time. Further studies are needed to understand the pathogenesis and risk factors related to the occurrence of HFS.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more